One-year real-life results on effect of intravitreal aflibercept in patients with diabetic macular oedema switched from ranibizumab.

Marko LukicGwyn WilliamsZaid ShalchiPraveen J PatelPhilip G HykinRobin D HamiltonRanjan Rajendram

Published in: European journal of ophthalmology (2020)

There was a significant improvement in visual acuity and in anatomical outcomes in the switched group at 12 months after commencing treatment with aflibercept for diabetic macular oedema.

Keyphrases

age related macular degeneration
diabetic retinopathy
type diabetes
wound healing
replacement therapy
weight loss
endothelial cells